AS601245
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 406237

CAS#: 345987-15-7

Description: AS601245 is a potent and selective JNK inhibitor. AS601245 decrease cell adhesion and migration through modulation of specific gene expression in human colon cancer cells. AS601245 and clofibrate have a synergistic effect in inducing cell responses and in affecting the cene expression profile in CaCo-2 colon cancer cells. AS601245 reduces axon/dendrite damage and cognitive deficits after global cerebral ischaemia in gerbils. AS601245 shows promising neuroprotective properties.


Chemical Structure

img
AS601245
CAS# 345987-15-7

Theoretical Analysis

MedKoo Cat#: 406237
Name: AS601245
CAS#: 345987-15-7
Chemical Formula: C20H16N6S
Exact Mass: 372.11572
Molecular Weight: 372.45
Elemental Analysis: C, 64.50; H, 4.33; N, 22.56; S, 8.61

Price and Availability

Size Price Availability Quantity
1.0g USD 2950.0 2 Weeks
2.0g USD 3950.0 2 Weeks
5.0g USD 5950.0 2 Weeks
Bulk inquiry

Synonym: AS601245; AS-601245; AS 601245.

IUPAC/Chemical Name: (Z)-2-(benzo[d]thiazol-2(3H)-ylidene)-2-(2-((2-(pyridin-3-yl)ethyl)amino)pyrimidin-4-yl)acetonitrile

InChi Key: AVLYNJZZQYEFEA-XDJHFCHBSA-N

InChi Code: InChI=1S/C20H16N6S/c21-12-15(19-25-17-5-1-2-6-18(17)27-19)16-8-11-24-20(26-16)23-10-7-14-4-3-9-22-13-14/h1-6,8-9,11,13,25H,7,10H2,(H,23,24,26)/b19-15+

SMILES Code: N#C/C(C1=NC(NCCC2=CC=CN=C2)=NC=C1)=C3SC4=CC=CC=C4N\3

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >5 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Product Data:

Biological target: AS601245 is an ATP competitive JNK (c-Jun NH2-terminal protein kinase) inhibitor with IC50s of 150, 220, and 70 nM for three JNK human isoforms (hJNK1, hJNK2, and hJNK3), respectively.
In vitro activity: Since the reduction of proliferation can be accompanied by the modulation of specific genes, this study determined the expression of proliferating cell nuclear antigen (PCNA), cyclin D1 and p21, in CaCo-2 cells. Moreover, this study found that AS601245 at the concentration of 0.1 μM was able to inhibit Jun phosphorylation in CaCo-2 cells. In Figure 2(a), the analysis of P-Jun expression revealed that the amount of P-Jun protein was reduced in cells treated with 0.1 μM AS601245. A similar result was observed in cells treated with AS601245 plus clofibrate. Reference: PPAR Res. 2012; 2012: 269751. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3349252/
In vivo activity: In vitro kinase assay in the LPS + HI mouse group confirmed that AS601245 (40 mg/kg) treatment significantly reduced JNK activity compared to vehicle treatment at 6 and 24 h post-insult (Figure 6A). In the LPS + HI group, AS601245 treatment significantly decreased the numbers of ED1-positive activated microglia, TNF-α immunoreactivities, BBB damage and cleaved caspase 3-positive cells in the white matter 24 h post-insult compared to vehicle treatment (Figure 6B). Further immunofluorescent staining showed that AS601245 markedly decreased the p-JNK (+) cells attached to or located around the microvessels (Figure 7A), and also greatly attenuated cleaved caspase 3 expression in vascular endothelial cells (Figure 7B) and oligodendroglial progenitor cells (Figure 7C). Compared to vehicle, AS601245 treatment on P2 at a dosage of 40 mg/kg but not 20 mg/kg in the LPS + HI group significantly preserved MBP expression (Figure 8A) and markedly attenuated astrogliosis by downregulating GFAP immunoreactivities (Figure 8B) in the white matter on P11. Reference: J Neuroinflammation. 2012 Jul 17;9:175. https://pubmed.ncbi.nlm.nih.gov/22805152/

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 6.0 16.11
DMF 2.0 5.37

Preparing Stock Solutions

The following data is based on the product molecular weight 372.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: 1. Cerbone A, Toaldo C, Pizzimenti S, Pettazzoni P, Dianzani C, Minelli R, Ciamporcero E, Roma G, Dianzani MU, Canaparo R, Ferretti C, Barrera G. AS601245, an Anti-Inflammatory JNK Inhibitor, and Clofibrate Have a Synergistic Effect in Inducing Cell Responses and in Affecting the Gene Expression Profile in CaCo-2 Colon Cancer Cells. PPAR Res. 2012;2012:269751. doi: 10.1155/2012/269751. Epub 2012 Feb 29. PMID: 22619672; PMCID: PMC3349252. 2. Wolschendorf F, Bosque A, Shishido T, Duverger A, Jones J, Planelles V, Kutsch O. Kinase control prevents HIV-1 reactivation in spite of high levels of induced NF-κB activity. J Virol. 2012 Apr;86(8):4548-58. doi: 10.1128/JVI.06726-11. Epub 2012 Feb 15. PMID: 22345467; PMCID: PMC3318643. 3. Wang LW, Tu YF, Huang CC, Ho CJ. JNK signaling is the shared pathway linking neuroinflammation, blood-brain barrier disruption, and oligodendroglial apoptosis in the white matter injury of the immature brain. J Neuroinflammation. 2012 Jul 17;9:175. doi: 10.1186/1742-2094-9-175. PMID: 22805152; PMCID: PMC3414763. 4. Carboni S, Boschert U, Gaillard P, Gotteland JP, Gillon JY, Vitte PA. AS601245, a c-Jun NH2-terminal kinase (JNK) inhibitor, reduces axon/dendrite damage and cognitive deficits after global cerebral ischaemia in gerbils. Br J Pharmacol. 2008 Jan;153(1):157-63. doi: 10.1038/sj.bjp.0707574. Epub 2007 Nov 19. PMID: 18026128; PMCID: PMC2199388.
In vitro protocol: 1. Cerbone A, Toaldo C, Pizzimenti S, Pettazzoni P, Dianzani C, Minelli R, Ciamporcero E, Roma G, Dianzani MU, Canaparo R, Ferretti C, Barrera G. AS601245, an Anti-Inflammatory JNK Inhibitor, and Clofibrate Have a Synergistic Effect in Inducing Cell Responses and in Affecting the Gene Expression Profile in CaCo-2 Colon Cancer Cells. PPAR Res. 2012;2012:269751. doi: 10.1155/2012/269751. Epub 2012 Feb 29. PMID: 22619672; PMCID: PMC3349252. 2. Wolschendorf F, Bosque A, Shishido T, Duverger A, Jones J, Planelles V, Kutsch O. Kinase control prevents HIV-1 reactivation in spite of high levels of induced NF-κB activity. J Virol. 2012 Apr;86(8):4548-58. doi: 10.1128/JVI.06726-11. Epub 2012 Feb 15. PMID: 22345467; PMCID: PMC3318643.
In vivo protocol: 1. Wang LW, Tu YF, Huang CC, Ho CJ. JNK signaling is the shared pathway linking neuroinflammation, blood-brain barrier disruption, and oligodendroglial apoptosis in the white matter injury of the immature brain. J Neuroinflammation. 2012 Jul 17;9:175. doi: 10.1186/1742-2094-9-175. PMID: 22805152; PMCID: PMC3414763. 2. Carboni S, Boschert U, Gaillard P, Gotteland JP, Gillon JY, Vitte PA. AS601245, a c-Jun NH2-terminal kinase (JNK) inhibitor, reduces axon/dendrite damage and cognitive deficits after global cerebral ischaemia in gerbils. Br J Pharmacol. 2008 Jan;153(1):157-63. doi: 10.1038/sj.bjp.0707574. Epub 2007 Nov 19. PMID: 18026128; PMCID: PMC2199388.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Cerbone A, Toaldo C, Minelli R, Ciamporcero E, Pizzimenti S, Pettazzoni P, Roma G, Dianzani MU, Ullio C, Ferretti C, Dianzani C, Barrera G. Rosiglitazone and AS601245 decrease cell adhesion and migration through modulation of specific gene expression in human colon cancer cells. PLoS One. 2012;7(6):e40149. doi: 10.1371/journal.pone.0040149. Epub 2012 Jun 28. PubMed PMID: 22761953; PubMed Central PMCID: PMC3386191.

2: Cerbone A, Toaldo C, Pizzimenti S, Pettazzoni P, Dianzani C, Minelli R, Ciamporcero E, Roma G, Dianzani MU, Canaparo R, Ferretti C, Barrera G. AS601245, an Anti-Inflammatory JNK Inhibitor, and Clofibrate Have a Synergistic Effect in Inducing Cell Responses and in Affecting the Gene Expression Profile in CaCo-2 Colon Cancer Cells. PPAR Res. 2012;2012:269751. doi: 10.1155/2012/269751. Epub 2012 Feb 29. PubMed PMID: 22619672; PubMed Central PMCID: PMC3349252.

3: Carboni S, Boschert U, Gaillard P, Gotteland JP, Gillon JY, Vitte PA. AS601245, a c-Jun NH2-terminal kinase (JNK) inhibitor, reduces axon/dendrite damage and cognitive deficits after global cerebral ischaemia in gerbils. Br J Pharmacol. 2008 Jan;153(1):157-63. Epub 2007 Nov 19. PubMed PMID: 18026128; PubMed Central PMCID: PMC2199388.

4: Carboni S, Hiver A, Szyndralewiez C, Gaillard P, Gotteland JP, Vitte PA. AS601245 (1,3-benzothiazol-2-yl (2-[[2-(3-pyridinyl) ethyl] amino]-4 pyrimidinyl) acetonitrile): a c-Jun NH2-terminal protein kinase inhibitor with neuroprotective properties. J Pharmacol Exp Ther. 2004 Jul;310(1):25-32. Epub 2004 Feb 26. PubMed PMID: 14988419.



Additional Information